Search results
Showing 1701 to 1750 of 2008 results for news
After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
NICE provisionally recommends leadless implantable pacemaker in draft guidance
A procedure for people with slow heart rhythms could be used more widely after it was recommended for NHS use in draft guidance.
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
Four AI technologies conditionally recommended to help detect undiagnosed fragility fractures
The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans.
Home News Podcasts NICE's prioritisation board: focus on what matters most Podcasts 27 June 2025 Listen About this episode In this...
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
Learn more about our updated maternal and child nutrition guideline
Home News Podcasts Learn more about our updated maternal and child nutrition guideline Podcasts 30 May 2025 Listen About this episode...
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
Home News Podcasts Will robotic-assisted surgery change NHS practice forever? Podcasts 30 April 2025 Listen About this episode In this...
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
Health inequalities - an update to NICE's methods for health technology evaluation
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
Technology recommended for people with chronic tic disorders and Tourette syndrome
Final guidance recommends one digital therapy to help children and young people manage their condition.
New guideline will help cut falls and related hospital admissions for older and at-risk people
Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.
This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a-G5 (on the register, within the preceding 12 months) who had eGFR and ACR (urine albumin to creatinine ratio) measurements recorded within 90 days before or after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM216
This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a–G5 (on the register, within the preceding 12 months) who had eGFR measured on at least 2 occasions separated by at least 90 days, and the second test within 90 days before the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM215.
This indicator covers the proportion of new cases of cancer with stage at diagnosis recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG02
Alcohol use: brief intervention for people with depression or anxiety (IND199)
This indicator covers the percentage of patients with a new diagnosis of depression or anxiety and a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 12 months, who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM178
Alcohol use: risk assessment for people with depression or anxiety (IND198)
This indicator covers the percentage of patients with a new diagnosis of depression or anxiety in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after their diagnosis being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM177
Alcohol use: brief intervention for people with hypertension (IND197)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months with a FAST score of 3 or more or AUDIT-C score of 5 or more who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM176
Alcohol use: risk assessment for people with hypertension (IND196)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after the date of entry on the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved
This indicator covers the percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional capacity (using the New York Heart Association classification) and a review of medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM174
This indicator covers the percentage of patients with a new diagnosis of asthma on or after (start date) with a record of an objective test between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Depression and anxiety: review within 10 to 35 days (IND104)
This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have been reviewed within 10 to 35 days of the date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM50
Depression and anxiety: biopsychosocial assessment at diagnosis (IND103)
This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have had a bio-psychosocial assessment by the point of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM49
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE chronic lung disease treatment decision could benefit 5,200 people
NICE broadens nintedanib recommendation on chronic lung disease treatment.
Improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance
NHS may use innovative tests which may help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly.
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations
Decision aid to guide discussions on sleeping pill prescriptions
A patient decision aid on medicines associated with dependence or withdrawal symptoms has been published
NICE recommends 8 digitally enabled therapies to treat depression and anxiety
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.
NICE draft guidance recommends new treatment for chronic heart failure
Up to 150,000 people in England with a type of chronic heart failure are set to benefit from a new treatment following its approval by NICE.
Two technologies to provide digital services for people with COPD
More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.
Ground-breaking CAR-T therapy to treat aggressive form of blood cancer approved
More than 400 people set to benefit after NICE recommends first personalised immunotherapy for lymphoma.
New Chief Medical Officer, Chief People Officer and Director of Implementation and Partnerships appointed by NICE.
Adults with depression who want to quit antidepressants should be given support
Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.